Journal ArticleDOI
Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity.
Reads0
Chats0
TLDR
An overview of the structure-affinity relationships that continue to drive development of new nAChR ligands is provided.Abstract:
In the last decade, nicotinic acetylcholine receptors (nAChRs) have emerged as important targets for drug discovery. The therapeutic potential of nicotinic agonists depends substantially on the ability to selectively activate certain receptor subtypes that mediate beneficial effects. The design of such compounds has proceeded in spite of a general shortage of data pertaining to subtype selectivity. Medicinal chemistry efforts have been guided principally by binding affinities to the α4β2 and / or α7 subtypes, even though these are not predictive of agonist activity at either subtype. Nevertheless, a diverse family of nAChR ligands has been developed, and several analogs with promising therapeutic potential have now advanced to human clinical trials. This paper provides an overview of the structure-affinity relationships that continue to drive development of new nAChR ligands.read more
Citations
More filters
Journal ArticleDOI
NEONICOTINOID INSECTICIDE TOXICOLOGY: Mechanisms of Selective Action
Motohiro Tomizawa,John E. Casida +1 more
TL;DR: The neonicotinoids have outstanding potency and systemic action for crop protection against piercing-sucking pests, and they are highly effective for flea control on cats and dogs.
Journal ArticleDOI
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Jotham Wadsworth Coe,Paige Roanne Palmer Brooks,Michael G. Vetelino,Michael C. Wirtz,Eric P. Arnold,Huang Jianhua,Steven B. Sands,Thomas I. Davis,Lorraine A. Lebel,Carol B. Fox,Alka Shrikhande,James Heym,Eric Schaeffer,Hans Rollema,Yi Lu,Robert S. Mansbach,Leslie K. Chambers,Charles C. Rovetti,David W. Schulz,and F. David Tingley,Brian T. O’Neill +20 more
TL;DR: Varenicline displays high α4β2 nAChR affinity and the desired in vivo dopaminergic profile and provides relief from the craving and withdrawal syndrome that accompanies cessation attempts.
Journal ArticleDOI
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
Journal ArticleDOI
Pain, Nicotine, and Smoking: Research Findings and Mechanistic Considerations.
TL;DR: In this article, the authors conceptualized the interaction of pain and smoking as a prototypical example of the biopsychosocial model and extrapolated from behavioral, cognitive, affective, biomedical, and social perspectives to propose causal mechanisms that may contribute to the observed comorbidity between these 2 conditions.
Journal ArticleDOI
Nicotinic agonists, antagonists, and modulators from natural sources.
TL;DR: Research on acetylcholine receptors and functions has been dependent on key natural products and the synthetic agents that they inspired, and galanthamine, codeine, and ivermectin represent positive modulators of nicotinic function, derived from natural sources.